Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial

Hans Salwender; Ahmet Elmaagacli; Maximilian Merz; Kaya Miah; Axel Benner; Mathias Haenel; Christian Jehn; Elias K Mai; Uta Bertsch; Igor W Blau; Christof Scheid; Dirk Hose; Anja Seckinger; Anna Jauch; Marc S Raab; Steffen P Luntz; Britta Besemer; Markus Munder; Peter Brossart; Stephan Fuhrmann; Hans-Walter Lindemann; Katja Weisel; Jan Duerig; Hartmut Goldschmidt

doi:10.1038/s41375-021-01298-y

Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial

Hans Salwender, Ahmet Elmaagacli, Maximilian Merz, Kaya Miah, Axel Benner, Mathias Haenel, Christian Jehn, Elias K Mai, Uta Bertsch, Igor W Blau, Christof Scheid, Dirk Hose, Anja Seckinger, Anna Jauch, Marc S Raab, Steffen P Luntz, Britta Besemer, Markus Munder, Peter Brossart, Stephan FuhrmannHans-Walter Lindemann, Katja Weisel, Jan Duerig, Hartmut Goldschmidt

Basic (bio-) Medical Sciences

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

Original language	English
Pages (from-to)	3007-3011
Number of pages	5
Journal	Leukemia
Volume	35
Issue number	10
DOIs	https://doi.org/10.1038/s41375-021-01298-y
Publication status	Published - Oct 2021

Bibliographical note

Funding Information:
Acknowledgements The GMMG-MM5 trial was supported by Cel-gene, Janssen-Cilag, Chugai, and The Binding Site. The GMMG thanks the Koordinierungszentrum für Klinische Studien (KKS) Heidelberg for the support of the trial and data monitoring. The GMMG thanks all participating investigators and centers.

Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.

Keywords

Administration, Intravenous/methods
Adolescent
Adult
Aged
Antineoplastic Agents/administration & dosage
Bortezomib/administration & dosage
Follow-Up Studies
Humans
Induction Chemotherapy/methods
Injections, Subcutaneous/methods
Maintenance Chemotherapy
Middle Aged
Multiple Myeloma/drug therapy
Prospective Studies
Young Adult

Access to Document

10.1038/s41375-021-01298-y

Cite this

Salwender, H., Elmaagacli, A., Merz, M., Miah, K., Benner, A., Haenel, M., Jehn, C., Mai, E. K., Bertsch, U., Blau, I. W., Scheid, C., Hose, D., Seckinger, A., Jauch, A., Raab, M. S., Luntz, S. P., Besemer, B., Munder, M., Brossart, P., ... Goldschmidt, H. (2021). Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial. Leukemia, 35(10), 3007-3011. https://doi.org/10.1038/s41375-021-01298-y

@article{a78230dc1b1542b4b98b770e800164f1,

title = "Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial",

keywords = "Administration, Intravenous/methods, Adolescent, Adult, Aged, Antineoplastic Agents/administration & dosage, Bortezomib/administration & dosage, Follow-Up Studies, Humans, Induction Chemotherapy/methods, Injections, Subcutaneous/methods, Maintenance Chemotherapy, Middle Aged, Multiple Myeloma/drug therapy, Prospective Studies, Young Adult",

author = "Hans Salwender and Ahmet Elmaagacli and Maximilian Merz and Kaya Miah and Axel Benner and Mathias Haenel and Christian Jehn and Mai, {Elias K} and Uta Bertsch and Blau, {Igor W} and Christof Scheid and Dirk Hose and Anja Seckinger and Anna Jauch and Raab, {Marc S} and Luntz, {Steffen P} and Britta Besemer and Markus Munder and Peter Brossart and Stephan Fuhrmann and Hans-Walter Lindemann and Katja Weisel and Jan Duerig and Hartmut Goldschmidt",

note = "Funding Information: Acknowledgements The GMMG-MM5 trial was supported by Cel-gene, Janssen-Cilag, Chugai, and The Binding Site. The GMMG thanks the Koordinierungszentrum f{\"u}r Klinische Studien (KKS) Heidelberg for the support of the trial and data monitoring. The GMMG thanks all participating investigators and centers. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",

year = "2021",

month = oct,

doi = "10.1038/s41375-021-01298-y",

language = "English",

volume = "35",

pages = "3007--3011",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "10",

}

Salwender, H, Elmaagacli, A, Merz, M, Miah, K, Benner, A, Haenel, M, Jehn, C, Mai, EK, Bertsch, U, Blau, IW, Scheid, C, Hose, D, Seckinger, A, Jauch, A, Raab, MS, Luntz, SP, Besemer, B, Munder, M, Brossart, P, Fuhrmann, S, Lindemann, H-W, Weisel, K, Duerig, J & Goldschmidt, H 2021, 'Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial', Leukemia, vol. 35, no. 10, pp. 3007-3011. https://doi.org/10.1038/s41375-021-01298-y

TY - JOUR

T1 - Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial

AU - Salwender, Hans

AU - Elmaagacli, Ahmet

AU - Merz, Maximilian

AU - Miah, Kaya

AU - Benner, Axel

AU - Haenel, Mathias

AU - Jehn, Christian

AU - Mai, Elias K

AU - Bertsch, Uta

AU - Blau, Igor W

AU - Scheid, Christof

AU - Hose, Dirk

AU - Seckinger, Anja

AU - Jauch, Anna

AU - Raab, Marc S

AU - Luntz, Steffen P

AU - Besemer, Britta

AU - Munder, Markus

AU - Brossart, Peter

AU - Fuhrmann, Stephan

AU - Lindemann, Hans-Walter

AU - Weisel, Katja

AU - Duerig, Jan

AU - Goldschmidt, Hartmut

N1 - Funding Information: Acknowledgements The GMMG-MM5 trial was supported by Cel-gene, Janssen-Cilag, Chugai, and The Binding Site. The GMMG thanks the Koordinierungszentrum für Klinische Studien (KKS) Heidelberg for the support of the trial and data monitoring. The GMMG thanks all participating investigators and centers. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.

PY - 2021/10

Y1 - 2021/10

KW - Administration, Intravenous/methods

KW - Adolescent

KW - Adult

KW - Aged

KW - Antineoplastic Agents/administration & dosage

KW - Bortezomib/administration & dosage

KW - Follow-Up Studies

KW - Humans

KW - Induction Chemotherapy/methods

KW - Injections, Subcutaneous/methods

KW - Maintenance Chemotherapy

KW - Middle Aged

KW - Multiple Myeloma/drug therapy

KW - Prospective Studies

KW - Young Adult

UR - http://www.scopus.com/inward/record.url?scp=85106229487&partnerID=8YFLogxK

U2 - 10.1038/s41375-021-01298-y

DO - 10.1038/s41375-021-01298-y

M3 - Article

C2 - 34031532

SN - 0887-6924

VL - 35

SP - 3007

EP - 3011

JO - Leukemia

JF - Leukemia

IS - 10

ER -

Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial

Bibliographical note

Keywords

Access to Document

Other files and links

Cite this